WRBY vs. BLCO, STAA, RXST, EYE, LUCY, ALC, COO, GKOS, ACHC, and MDGL
Should you be buying Warby Parker stock or one of its competitors? The main competitors of Warby Parker include Bausch + Lomb (BLCO), STAAR Surgical (STAA), RxSight (RXST), National Vision (EYE), Innovative Eyewear (LUCY), Alcon (ALC), Cooper Companies (COO), Glaukos (GKOS), Acadia Healthcare (ACHC), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "medical" sector.
Warby Parker (NYSE:WRBY) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, community ranking, risk and valuation.
Warby Parker currently has a consensus target price of $16.43, suggesting a potential downside of 0.58%. Bausch + Lomb has a consensus target price of $18.95, suggesting a potential upside of 19.89%. Given Bausch + Lomb's stronger consensus rating and higher probable upside, analysts plainly believe Bausch + Lomb is more favorable than Warby Parker.
Bausch + Lomb received 1 more outperform votes than Warby Parker when rated by MarketBeat users. Likewise, 39.06% of users gave Bausch + Lomb an outperform vote while only 32.43% of users gave Warby Parker an outperform vote.
In the previous week, Warby Parker and Warby Parker both had 9 articles in the media. Warby Parker's average media sentiment score of 0.63 beat Bausch + Lomb's score of 0.15 indicating that Warby Parker is being referred to more favorably in the media.
Warby Parker has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500.
Warby Parker has higher earnings, but lower revenue than Bausch + Lomb. Warby Parker is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.
Bausch + Lomb has a net margin of -7.81% compared to Warby Parker's net margin of -7.89%. Bausch + Lomb's return on equity of 3.60% beat Warby Parker's return on equity.
93.2% of Warby Parker shares are held by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are held by institutional investors. 26.5% of Warby Parker shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Bausch + Lomb beats Warby Parker on 10 of the 17 factors compared between the two stocks.
Get Warby Parker News Delivered to You Automatically
Sign up to receive the latest news and ratings for WRBY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WRBY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Warby Parker Competitors List
Related Companies and Tools
